glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection

Part of Weight Loss Drug Comparison Index.

Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection

Foundayo (orforglipron) and Zepbound (tirzepatide) are both FDA-approved options for adult weight management. Foundayo is a daily pill without a fasting requirement; Zepbound is a weekly injection. Zepbound’s separate obesity trial reported greater average weight loss, but those results do not prove that it is “twice as effective” for the same patient. Foundayo label, Zepbound label
The practical comparison is now daily routine, treatment response, side effects, coverage and maintenance cost, rather than whether to wait for orforglipron’s approval. If you are already taking Zepbound, the switching evidence matters too: changing to a pill may involve weight regain.
Reviewed September 8, 2026. Prices below are US manufacturer offers with eligibility conditions, not guaranteed pharmacy costs.

Side-by-Side Comparison

Foundayo (orforglipron)Zepbound (tirzepatide)
DeveloperEli LillyEli Lilly
RouteDaily oral tabletWeekly injection under the skin
ReceptorsGLP-1GLP-1 and GIP
Adult weight managementFDA-approvedFDA-approved
Obesity-related OSANo indication in the current labelApproved for moderate-to-severe OSA in adults with obesity
Maximum labeled dose17.2 mg daily15 mg weekly
Fasting requirementNoneNone
StorageRoom temperature under labeled conditionsRefrigeration and room-temperature limits depend on device
Advertised self-pay starting offer$149 per 30 days; conditions apply$299 per 28 days for KwikPen; conditions apply
Both weight-management indications apply to adults with obesity, or overweight with a weight-related condition, alongside diet and activity. Sources: Foundayo label, Zepbound label, Foundayo savings terms and Zepbound savings terms.

How They Work Differently

Orforglipron: Oral Small Molecule, One Receptor

Orforglipron is a non-peptide GLP-1 receptor agonist that reduces calorie intake through effects on appetite. Foundayo can be taken with or without food. Unlike oral semaglutide, it does not require an empty-stomach routine, but it still has dose-escalation instructions and drug interactions. Foundayo clinical pharmacology and administration

Claims about receptor signaling do not establish that the pill will cause less desensitization, be safer or work for longer in clinical use.

Zepbound: Injectable Dual Agonist, Two Receptors

Tirzepatide activates both GLP-1 and GIP receptors. It reduces calorie intake and is administered weekly. The receptor difference does not, by itself, explain a numerical gap between unrelated trials. Zepbound clinical pharmacology
Storage instructions are device-specific. Single-dose pens and vials are refrigerated but can be kept at room temperature up to 30°C for a total of 21 days. Multi-dose vials and KwikPens have different limits, including disposal after a total of 30 days at room temperature, 30 days after first use or four weekly doses. Follow the instructions supplied with your product; “Zepbound vials need no refrigeration” is not a reliable rule. Zepbound storage instructions, section 16.2

Weight Loss Comparison

Phase 3 Trial Results

These 72-week trials enrolled adults without diabetes. The main figures below come from the current labels’ intention-to-treat analyses, which include all randomized participants with missing outcomes imputed.

Swipe sideways to see every column.

Treatment described in labelTrialTotal randomizedMean weight change
Foundayo-equivalent 5.5 mg dailyATTAIN-13,127−7.4%
Foundayo-equivalent 9 mg dailyATTAIN-13,127−8.3%
Foundayo-equivalent 17.2 mg dailyATTAIN-13,127−11.1%
Zepbound 5 mg weeklySURMOUNT-12,539−15.0%
Zepbound 10 mg weeklySURMOUNT-12,539−19.5%
Zepbound 15 mg weeklySURMOUNT-12,539−20.9%
Placebo mean reductions were 2.1% in the Foundayo label’s Trial 1 and 3.1% in the Zepbound label’s Study 1. These were separate populations and protocols, not a randomized Foundayo-versus-Zepbound comparison. Foundayo label, Table 6, Zepbound label, Table 2
You may also see 12.4% for orforglipron and 22.5% for Zepbound. Those are the published efficacy-estimand results, which address treatment discontinuation differently. The 36 mg orforglipron figure refers to an investigational formulation; the current Foundayo label expresses trial doses as equivalent marketed doses, with a maximum marketed dose of 17.2 mg. ATTAIN-1 full results, SURMOUNT-1 full results

Weight Loss Thresholds

At 72 weeks, the labels report that 35.9% of the highest-dose Foundayo-equivalent group and 70.6% of the Zepbound 15 mg group lost at least 15% of body weight. For at least 20% weight loss, the figures were 18.4% and 56.7%. These are intention-to-treat estimates from separate studies, not a forecast for a particular patient. Foundayo label, Zepbound label

Important Caveats

Zepbound’s numerically larger trial results are relevant context, but the comparison cannot isolate the drug effect from differences in participants, treatment protocols and analysis. Nor does a trial average establish a first-line choice for someone who wants to lose a particular percentage of weight. Tolerability and the ability to continue treatment also matter.

Side Effects Comparison

Both medicines can cause nausea, diarrhea, vomiting and constipation. Reported rates below are from the named trial arms, not a head-to-head safety study.

Reported adverse eventOrforglipron 36 mg trial formulation, ATTAIN-1Zepbound 15 mg, SURMOUNT-1
Nausea33.7%31.0%
Diarrhea23.1%23.0%
Vomiting24.0%12.2%
Constipation25.4%11.7%
Stopped treatment because of adverse events10.3%6.2%
Sources: ATTAIN-1 full results and SURMOUNT-1 full results. Do not use these unrelated trial rates to conclude that one product causes more nausea, is safer or will be easier for you to tolerate. The studies do not establish an explanation based on daily versus weekly gastrointestinal exposure.
Both labels warn about pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury and gallbladder disease. Both have boxed thyroid C-cell tumor warnings and contraindications for a personal or family history of medullary thyroid carcinoma or MEN 2. Zepbound can cause injection-site reactions; Foundayo has specific CYP3A4 and simvastatin interactions. Foundayo label, Zepbound label

Ask your clinician about persistent symptoms, pregnancy plans, other medicines and planned procedures. Choosing a pill does not remove the need for safety monitoring.

Cost and Access

Current Manufacturer Pricing

As checked on September 8, 2026, Lilly lists these US self-pay offer prices. The rows are price categories, not equivalent doses.
Product and doseOffer price for one supplyImportant condition
Foundayo 0.8 mg$149 / 30 daysStarting dose; eligibility applies
Foundayo 2.5 mg$149 / 30 daysTemporary price through December 31, 2026
Foundayo 5.5 mg$199 / 30 daysTemporary price through December 31, 2026
Foundayo 9 mg$299 / 30 daysEligibility applies
Foundayo 14.5 or 17.2 mg$299 / 30 daysContinued offer requires qualifying refills within 45 days
Zepbound KwikPen 2.5 mg$299 / 28 daysStarting dose, not a maintenance dose
Zepbound KwikPen 5 mg$399 / 28 daysEligibility applies
Zepbound KwikPen 7.5, 10, 12.5 or 15 mg$449 / 28 daysContinued offer requires qualifying refills within 45 days
Sources: Foundayo coverage and savings terms and Zepbound coverage and savings terms. Refill deadlines are measured from delivery or receipt of the preceding prescription under the respective offer. Taxes or fees may apply, and Lilly can change the terms. Zepbound’s single-dose pen, vial and KwikPen offers are not automatically interchangeable.
The maintenance-dose bill matters more than the entry price. Confirm which product your plan covers, which program you qualify for, and what you pay if an introductory or refill offer ends. Chemistry alone does not establish a cost advantage.

Access Differences

Both medicines are prescription options now. Foundayo’s label covers adult weight management; Zepbound also covers moderate-to-severe OSA in adults with obesity. A clinician should assess the indication and relevant risks. Foundayo label, Zepbound label
Medicare is no longer a simple “Foundayo $50, Zepbound not covered” comparison. The Medicare GLP-1 Bridge began July 1, 2026 and includes Foundayo tablets and Zepbound KwikPen for eligible beneficiaries, with a $50 payment for a one-month supply. It has specific eligibility and authorization requirements; it does not cover Zepbound single-dose pens or vials through this pathway. Check Medicare’s weight-loss drug coverage page with the prescriber rather than assuming that every Medicare patient qualifies.

Convenience vs Efficacy: The Core Decision

The Case for Orforglipron

A daily Foundayo tablet may fit someone who does not want injections or finds the semaglutide-pill fasting routine difficult. It uses room-temperature storage and has current self-pay offers. Its fit still depends on the indication, interactions, response and the cost of staying on the prescribed dose. Foundayo label

The Case for Zepbound

A weekly routine may be easier to maintain than a daily tablet. Zepbound has an additional indication for moderate-to-severe OSA in adults with obesity and a longer history of clinical use. If it is already working and tolerable, a switch is not automatically an improvement. Zepbound label
Mounjaro contains the same active ingredient but has a separate diabetes and cardiovascular label. Its August 2026 cardiovascular indication should not be presented as a Zepbound indication. See Orforglipron vs Tirzepatide for that distinction. Mounjaro label

Who Might Choose Which?

Bring three questions to the appointment: Which approved use applies to me? What would make us change or stop the treatment? Can I sustain the routine and cost? Someone doing well on Zepbound may decide to continue; someone unable to use injections may discuss Foundayo. Neither decision should be based only on a desired percentage of weight loss or the lowest advertised starting price.

Switching Between the Two

ATTAIN-MAINTAIN studied 376 people after they completed SURMOUNT-5. Participants were randomized to orforglipron or placebo for a further 52 weeks. Lilly’s May 2026 detailed report, accompanying publication in Nature Medicine, found that the prior-Zepbound cohort switching to orforglipron regained 5.0 kg on average in the reported efficacy analysis. Detailed ATTAIN-MAINTAIN results
That figure is change after switching, not a difference from people who stayed on Zepbound. This trial had no continued-Zepbound comparison arm. Rescue treatment was allowed under specified conditions, and the efficacy analysis made assumptions about adherence and rescue treatment.
The evidence supports discussing an oral maintenance option, while allowing for regain and follow-up. It does not prove that switching preserves as much weight loss as continuing Zepbound. There is no milligram-for-milligram conversion, and the labels do not recommend using Foundayo and Zepbound together. Foundayo label, Zepbound label

Where Retatrutide Fits

Retatrutide remains an investigational weekly injection. Lilly reported 28.7% average weight loss at 68 weeks with 12 mg in TRIUMPH-4’s efficacy analysis, in adults with obesity or overweight and knee osteoarthritis, without diabetes. This is a different population and trial; it does not establish that retatrutide is superior to either approved treatment here. TRIUMPH-4 topline report
See Retatrutide vs Tirzepatide and Retatrutide vs Orforglipron for the investigational comparison.

Frequently Asked Questions

Is orforglipron as effective as Zepbound for weight loss?

Zepbound’s trial reported larger average reductions, but the two drugs were not compared directly in those obesity studies. Different populations and analyses prevent a claim that Zepbound is “twice as effective” for the same patient. Both are approved weight-management options for eligible adults.

Is orforglipron cheaper than Zepbound?

Foundayo’s listed self-pay offers are lower than the Zepbound KwikPen offers shown above, but your cost depends on dose, product, insurance and program eligibility. Compare maintenance costs and refill conditions. Starting prices are not a guarantee of long-term cost.

Are orforglipron and Zepbound made by the same company?

Yes. Eli Lilly markets orforglipron as Foundayo and tirzepatide as Zepbound. Both have adult weight-management indications. Lilly is also studying retatrutide, which is not an approved alternative.

Can I switch from Zepbound to orforglipron?

A clinician can consider Foundayo for oral maintenance. ATTAIN-MAINTAIN found an average 5.0 kg regain over 52 weeks in the prior-Zepbound cohort under its efficacy analysis. It compared switching with placebo, not continuing Zepbound, so it does not prove equivalent maintenance or provide a dose conversion.

When will orforglipron be available?

It is already available in the US as prescription Foundayo for adult weight management. The former expectation of a Q2 2026 FDA decision is outdated.

Should I wait for orforglipron or start Zepbound now?

You no longer need to wait for US approval of orforglipron: Foundayo is approved. Discuss the available options with a clinician, including the relevant indication, previous response, side effects, daily versus weekly routine and continuing cost.

What are the side effects of orforglipron compared to Zepbound?

Both can cause gastrointestinal symptoms and have serious warnings. Zepbound can cause injection-site reactions; Foundayo has specific medicine interactions. Separate trial rates cannot tell you which will be safer or better tolerated for you.

Sources

  1. Eli Lilly. Foundayo prescribing information.
  2. Eli Lilly. Zepbound prescribing information.
  3. Eli Lilly. Mounjaro prescribing information.
  4. Eli Lilly. ATTAIN-1 full results. September 16, 2025.
  5. Eli Lilly. SURMOUNT-1 full results. June 4, 2022.
  6. Eli Lilly. ATTAIN-MAINTAIN detailed results. May 12, 2026.
  7. Eli Lilly. Foundayo coverage and savings and Zepbound coverage and savings. Checked September 8, 2026.
  8. Medicare. Weight-loss drug coverage and GLP-1 Bridge.
  9. Eli Lilly. TRIUMPH-4 topline results. December 11, 2025.
This article is for information, not a prescription or switching plan. Foundayo and Zepbound are FDA-approved for their respective labeled uses; retatrutide remains investigational. Discuss treatment with your clinician. This site is not affiliated with Eli Lilly or any pharmaceutical manufacturer.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo and Zepbound are FDA-approved for adult weight management under their respective labels. Zepbound also has an obesity-related obstructive sleep apnea indication. Retatrutide remains investigational.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →